Science Pool

New Approaches in Toxicology – Chris Strock, Cyprotex

Seizure Prediction using MEA: Importance of Receptor Expression, Cell Type, and Maturity

The fourth webinar in this series on New Approaches in Toxicology was presented by Christopher Strock PhD from Cyprotex.


About the Webinar


For the prediction of seizurogenic and neurotoxic compounds, microelectrode array (MEA) technology has proven to be a very powerful tool. Early human induced potent stem cell (hiPSC) derived neuronal models lacked complex burst organization, making electrophysiological neurotoxic prediction challenging when utilizing an MEA platform. However, advancements in hiPSC neuronal models have addressed these challenges. In this presentation, we learn more about how maturation of the hiPSC model is critical for neuronal characteristics such as bursting and synchrony, we demonstrate how time dependent receptor expression plays a role in this maturation process, and we understand the impact of different cell types and co-culture models on the sensitivity and robustness of the neuronal and seizurogenic activity.


About the Speaker


Chris Strock

Christopher Strock PhD

Director of Scientific Operations | Cyprotex

Chris Strock received his BS in Chemistry from Gannon University in Erie, PA. He worked as an organic chemist for DuPont Ag for a few years before getting his PhD in Biochemistry and Molecular Biology from the University of Maryland, Baltimore where he determined the calcium binding sites on the SR Calcium. Following his PhD, Chris was a Postdoctoral Fellow and Research Associate in the Oncology Department at Johns Hopkins University School of Medicine under Barry Nelkin, PhD where he identified CDK5, a protein important in migration of cells in neural development, as an essential molecule for metastasis in numerous cancer models. He then joined Cellumen where he developed his expertise in High Content Screening technology. While there, he specialized in assay development and was responsible for the design and development of High Content HTS Protein: Protein Interaction biosensor assays. He also worked in the HCS toxicology group, developing and optimizing assays for the in vitro toxicology assay, CellCiphr®. After Cyprotex acquired Cellumen, Chris joined Cyprotex US in Watertown, MA where he has brought his expertise for the last 10 years in the area of HCS assay development, electrophysiology and toxicology. He is the co- chairman of the HesI NeuTox Group for prediction of Seizures using Microelectrode Array. He currently is the Watertown Site Head and the Head of the in vitro Toxicology group and has more than 30 peer reviewed publications.

Watch the webinar to learn more!